These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17652815)

  • 21. [Cardiotoxicity of anthracyclines: mechanisms and pharmacologic targets for prevention].
    Andrieu-Abadie N
    Therapie; 2004; 59(1):121-6. PubMed ID: 15199678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
    Xu X; Sutak R; Richardson DR
    Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
    Menna P; Recalcati S; Cairo G; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress.
    Gratia S; Kay L; Potenza L; Seffouh A; Novel-Chaté V; Schnebelen C; Sestili P; Schlattner U; Tokarska-Schlattner M
    Cardiovasc Res; 2012 Aug; 95(3):290-9. PubMed ID: 22461523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
    Ghigo A; Li M; Hirsch E
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ranolazine in the prevention of anthracycline-related cardiotoxicity].
    Corradi F; Paolini L; De Caterina R
    G Ital Cardiol (Rome); 2013 Jun; 14(6):424-37. PubMed ID: 23748539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
    Popelová O; Sterba M; Hasková P; Simůnek T; Hroch M; Guncová I; Nachtigal P; Adamcová M; Gersl V; Mazurová Y
    Br J Cancer; 2009 Sep; 101(5):792-802. PubMed ID: 19623174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Theoretical ground for adsorptive therapy of anthracyclines cardiotoxicity.
    Shevchuk OO; Posokhova EA; Sakhno LA; Nikolaev VG
    Exp Oncol; 2012 Dec; 34(4):314-22. PubMed ID: 23302988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenesis of cardiotoxicity induced by anthracyclines.
    Elliott P
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios.
    Dorr RT; Bozak KA; Shipp NG; Hendrix M; Alberts DS; Ahmann F
    Cancer Res; 1988 Sep; 48(18):5222-7. PubMed ID: 3409247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anthracycline Chemotherapy and Cardiotoxicity.
    McGowan JV; Chung R; Maulik A; Piotrowska I; Walker JM; Yellon DM
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):63-75. PubMed ID: 28185035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
    van Dalen EC; Caron HN; Kremer LC
    Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
    van Dalen EC; van den Brug M; Caron HN; Kremer LC
    Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage.
    Fogli S; Nieri P; Breschi MC
    FASEB J; 2004 Apr; 18(6):664-75. PubMed ID: 15054088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular basis of anthracycline-induced cardiotoxicity and its prevention.
    Horenstein MS; Vander Heide RS; L'Ecuyer TJ
    Mol Genet Metab; 2000; 71(1-2):436-44. PubMed ID: 11001837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is restoring regenerative potential a way to prevent anthracycline cardiotoxicity? A hypothesis.
    Koller A; Haid C
    Med Sci Monit; 2005 Jul; 11(7):HY21-23. PubMed ID: 15990696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity.
    Swift L; McHowat J; Sarvazyan N
    Cancer Res; 2003 Sep; 63(18):5992-8. PubMed ID: 14522926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular considerations with anthracycline use in patients with cancer.
    Nelson MA; Frishman WH; Seiter K; Keefe D; Dutcher J
    Heart Dis; 2001; 3(3):157-68. PubMed ID: 11975787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.